Quantcast

Latest Angina pectoris Stories

2010-12-01 06:28:00

DUBLIN, Dec. 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of Firazyr (icatibant) for treatment of acute attacks of hereditary angioedema (HAE). The study showed that patients receiving treatment with Firazyr experienced a significantly faster time to onset of symptom relief from...

2010-12-01 06:00:00

DUBLIN, December 1, 2010 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced topline results from FAST-3 (For Angioedema Subcutaneous Treatment), the largest of the Phase III trials studying the use of FIRAZYR(R) (icatibant) for treatment of acute attacks of hereditary angioedema (HAE). The study showed that patients receiving treatment with FIRAZYR experienced a significantly faster time to onset of symptom...

2010-11-15 08:00:00

SAN DIEGO, Nov. 15, 2010 /PRNewswire/ -- Cardium Therapeutics (NYSE Amex: CXM) reported on the presentation of results from the Company's sponsored preclinical research at the American Heart Association 2010 Annual Meeting Scientific Sessions being held November 13 - 17, 2010 in Chicago, IL. The new findings showed that coronary artery occlusion and reperfusion can substantially increase adenovector-mediated gene delivery to the heart, which is used in the Company's Generx product...

2010-10-22 00:00:38

New evidence confirming improved endothelial function in patients with symptomatic coronary artery disease, in a randomized, sham-controlled clinical trial Westbury, NY (Vocus) October 21, 2010 Vasomedical, Inc. ("Vasomedical") (OTC: VASO.OB), a world leader in the noninvasive treatment of cardiovascular diseases, today announced the online publication, on October 4, 2010 in the journal Circulation, of new evidence confirming improved endothelial function in patients with symptomatic...

2010-09-25 06:00:00

PHILADELPHIA, Sept. 25 /PRNewswire/ -- Today Astellas Pharma US, Inc. ("Astellas") announced results of a Phase IV study showing Lexiscan® (regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies(1). Results were presented during an oral presentation today at...

2010-09-02 06:00:00

IRVINE, Calif., Sept. 2 /PRNewswire/ -- Cardiogenesis Corporation (OTCQB: CGCP), released comments today regarding the STAR-heart study. The STAR-heart study, which was presented at the European Society of Cardiology 2010 Congress in August 2010, reported that the intracoronary injection of autologous stem cells derived from bone marrow is associated with improved hemodynamics and long term survival in the treatment of chronic heart failure. The study involved 391 patients with chronic...

2010-07-08 13:57:42

Women who have the most serious form of angina are three times as likely to develop severe coronary artery disease (CAD) as men with the same condition, according to the July issue of the Journal of Internal Medicine. Canadian researchers looked at the records of 23,771 patients referred for first diagnostic angiography over a six-year period. They found that women over the age of 60 with CCS Class IV angina (as defined by the Canadian Cardiovascular Society) faced a 21% higher absolute risk...

2010-06-10 08:00:00

SAN DIEGO, June 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Amex: CXM) today announced that it has entered into a Master Services Agreement with bioRASI, an international contract research organization, to assist Cardium in the conduct of a planned late-stage clinical study and commercialization activities for Cardium's Generx (Ad5FGF-4) drug candidate in Russia and affiliated jurisdictions, as well as in potentially other newly industrializing markets. Under the terms of the...

2010-04-20 12:47:08

The growing number of Americans with cardiovascular disease has caused a heightened sensitivity in the evaluation of chest pain. In a study published in the April issue of Mayo Clinic Proceedings researchers reported that patients dismissed from the hospital with noncardiac chest pain continue to experience cardiac events, which may highlight a need for more aggressive cardiovascular risk factor management in this population. Noncardiac chest pain is defined as a substernal chest pain in the...

2010-03-16 11:47:00

-- Data Presented at the American College of Cardiology 2010 Annual Meeting Suggests Treatment with the Neovasc Reducer Is Safe and Improves Angina Symptoms for at Least Three Years -- TSX Venture Exchange: NVC VANCOUVER and ATLANTA, March 16 /PRNewswire-FirstCall/ - Neovasc Inc. (TSXV: NVC), a developer of novel technologies used to treat vascular disease, today presented results from the follow-up phase of the initial clinical trial of its Neovasc Reducer(TM) product at the American...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related